{"id":"metoprolol-plus-morphine","safety":{"commonSideEffects":[{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Respiratory depression"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metoprolol is a selective beta-1 blocker that decreases cardiac contractility and heart rate, reducing myocardial oxygen demand and lowering blood pressure. Morphine acts as a mu-opioid receptor agonist to provide pain relief and anxiolysis, and also causes peripheral vasodilation and reduced sympathetic tone. Together, this combination reduces cardiac workload and provides analgesia, commonly used in acute coronary syndromes and acute heart failure.","oneSentence":"Metoprolol reduces heart rate and blood pressure via beta-1 adrenergic blockade, while morphine provides analgesia and reduces anxiety through opioid receptor agonism and sympathetic nervous system depression.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:55:03.522Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome with pain and hemodynamic management"},{"name":"Acute decompensated heart failure with pain"},{"name":"Myocardial infarction with anxiety and pain control"}]},"trialDetails":[{"nctId":"NCT01845194","phase":"PHASE1","title":"Repeated Dose Study for the Investigation of Heritability of and Genetic Influences on Drug Pharmacokinetics","status":"COMPLETED","sponsor":"Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH","startDate":"2009-12","conditions":"Drug Biotransformation, Membrane Transport","enrollment":117},{"nctId":"NCT00718406","phase":"PHASE4","title":"Pain Relief of Metoprolol Versus Metoprolol Plus Morphine in Acute Chest Pain","status":"COMPLETED","sponsor":"Sahlgrenska University Hospital","startDate":"","conditions":"Acute Coronary Syndromes","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"metoprolol plus morphine","genericName":"metoprolol plus morphine","companyName":"Sahlgrenska University Hospital","companyId":"sahlgrenska-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metoprolol reduces heart rate and blood pressure via beta-1 adrenergic blockade, while morphine provides analgesia and reduces anxiety through opioid receptor agonism and sympathetic nervous system depression. Used for Acute coronary syndrome with pain and hemodynamic management, Acute decompensated heart failure with pain, Myocardial infarction with anxiety and pain control.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}